2017-18 HSC Section 4 Green Book

B E L E ZNAY E T A L

NR NR LE vision: 20/25 United States 17

Case Type of Filler Injection Site Symptoms Signs Management 48 HA Glabella, cheeks 1 minute: vision loss in the inferior half of the RE NR Immediate: 500 mg acetazolamide 49 HA Nasal tip Immediate: LE vision loss, pain in the left upper face 50 HA Nose LE vision: 20/400, headache NR NR LE vision: 20/1,000 China 7 China 7 for Follow-up) Country RE vision recovery, visual field defect improved Germany 24 Day 2: violaceous, reticulated, ulcerative patches, ophthalmoplegia Day 2: IV methylprednisolone · 3 days, then tapered oral prednisolone; aspirin 100 mg orally LE vision loss; recovery from ophthalmoplegia and skin necrosis Korea 25

52 HA Forehead LE vision hand movement NR NR LE vision: 20/1,000 China 7 53 HA Upper eyelid LE vision loss, dizziness, vomiting

Ophthalmoplegia, ptosis NR LE vision loss China 7 54 HA Nose RE vision loss, dizziness, vomiting Korea 26

Ophthalmoplegia, ptosis NR RE vision loss China 7

57 HA NLF and glabella Immediate: RE Ophthalmoplegia, ptosis, exotropia Intra-arterial thrombolysis RE vision loss Korea 18 58 HA NLF 2 weeks: LE vision: 20/20 (1), inferior visual field defect NR NR LE vision: 20/20 (1), no comment on visual field defect Korea 18 59 HA Glabella 5 hours: LE vision: 20/30 (0.7), inferior visual field defect NR Massage, anterior chamber paracentesis LE vision: 20/130 (0.15) Korea 18 vision loss, pain

Outcome

ophthalmoplegia

51 HA Periorbital RE vision counting fingers 33 cm NR NR RE vision counting fingers 33 cm

(Variable Time

Ophthalmoplegia, ptosis High-dose IV corticosteroids RE vision loss,

55 HA Nasal dorsum Immediate: RE 56 HA Forehead 3 weeks: LE vision: 20/30, superior field vision loss vision loss, periocular pain

TABLE 1. (Continued)

4 1 : 1 0 : OCTOB E R 2 0 1 5

67